Bruker (BRKR) announced that Bruker and 10x Genomics (TXG) have reached a final settlement to resolve their patent disputes and dismiss multiple litigations, with global patent cross license agreements between the two companies. In connection with the settlement, all ongoing lawsuits and administrative proceedings filed by both companies in several countries, including actions pending in the United States, in Germany, and before the European Unified Patent Court, will be withdrawn.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- AbCellera says Federal Circuit rejects Bruker Cellular’s invalidity challenge
- Bruker price target lowered to $45 from $57 at UBS
- Bruker price target lowered to $48 from $57 at Stifel
- Bruker price target lowered to $46 from $50 at Barclays
- Bruker: Resilient Performance and Strategic Positioning Amidst 2025 Challenges